NIRS Monitoring to Detect AKI in Preterm Infants (nNIRS-AKI)

October 28, 2022 updated by: University of Wisconsin, Madison

Use of NIRS to Detect Acute Kidney Injury in Preterm Infants

This study will examine the relationship of oxygen levels, using Near-infrared spectroscopy (NIRS) monitoring, and kidney injury in infants born prematurely. NIRS is a skin sensor which detects the amount of oxygen going to different organs, most often used to monitor the brain and kidney.

Study Overview

Status

Completed

Intervention / Treatment

Detailed Description

This prospective, single-center study was conducted at UnityPoint Health-Meriter Hospital (Madison, WI, USA) in preterm neonates admitted to a level III NICU from April 2018 to August 2019. The primary study aim was to assess changes in RrSO2 with continuous renal NIRS monitoring to detect AKI during the first 7 days of age.

The INVOS 5100 C (Somanetics, Troy, MI, USA) four channel NIRS monitors were used to measure RrSO2 (measured at the right or left flank) and Cerebral regional Somatic tissue Oxygenation (CrSO2; measured at the forehead) for all neonates. At each measurement site, for skin protection, subjects had a transparent Mepitel (with Safetac Technology, Norcross, GA) adhesive dressing placed with the adhesive neonatal NIRS sensor (INVOS OxyAlert NIRSensor, Covidien) adhered over the Mepitel dressing. Neither cerebral or kidney sensors were placed with ultrasound guidance. Tissue oxygenation was recorded every 3 seconds until 7 days of age, and the sensor was changed one time when the patient reached three to four days of age per the company's recommendation. There were no restrictions on positioning or handling of neonates; nurses re-positioned neonates every 3-6 hours per unit protocol to prevent skin pressure injuries. Researchers, staff, and parents were blinded to RrSO2 values.

Study Type

Observational

Enrollment (Actual)

35

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

    • Wisconsin
      • Madison, Wisconsin, United States, 53715-1507
        • UnityPoint Health Meriter Hospital

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

3 years to 3 years (Child)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Sampling Method

Non-Probability Sample

Study Population

Preterm infants that are less than 32 weeks, admitted to Unity Point Health(UPH) Meriter Newborn Intensive Care Unit (NICU) with application of NIRS by 48 hours of age.

Description

Inclusion Criteria:

  • Preterm infants < 32 weeks
  • Admitted to Unity Point Health(UPH) Meriter Newborn Intensive Care Unit (NICU)
  • Application of NIRS by 48 hours of age

Exclusion Criteria:

  • Congenital anomaly of the kidney or urinary tract (CAKUT)

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Observational Models: Cohort
  • Time Perspectives: Prospective

Cohorts and Interventions

Group / Cohort
Intervention / Treatment
NIRS monitoring
These infants will be monitored with NIRS
Application of regional NIRS sensors to brain and kidney sites in the first 48 hours after birth to monitor regional tissue oxygenation for the first 7 days of age.
Other Names:
  • NIRS

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Renal NIRS Tissue Oxygenation Differential
Time Frame: Up to 1 week

Comparison of Renal saturation (Rsat) in neonates with AKI to those without AKI. RSO2 will be recorded until 7 days of age. Median RSO2 for 1 week and median for individual days 2-7 will be calculated.

The INVOS 5100 C (Somanetics, Troy, MI, USA) four channel NIRS monitors will be used to measure renal regional oxygenation (RrSO2) values for all neonates.

Up to 1 week

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Correlation of Renal NIRS Values to Serum Creatinine
Time Frame: Days 1-7 of age
At each time a serum creatinine was collected, the RrSO2 value was recorded.
Days 1-7 of age
Correlation of Renal NIRS Values to Urine Output
Time Frame: Days 1-7 of age
In patients with urine output recorded, it was compared to RrSO2 values
Days 1-7 of age
Baseline Renal NIRS Values Before Caffeine
Time Frame: Baseline (6 hours prior to caffeine dose)
these are the average renal NIRS values over 6 hours prior to a dose of caffeine broken down by percentage
Baseline (6 hours prior to caffeine dose)
Renal NIRS Values 1 Hour After Caffeine
Time Frame: At 1 hour after caffeine dose
Renal NIRS values one hour after caffeine broken down by baseline average.
At 1 hour after caffeine dose
Renal NIRS Values 2 Hours After Caffeine
Time Frame: At 2 hours after caffeine dose
Renal NIRS values 2 hours after caffeine broken down by baseline average
At 2 hours after caffeine dose
Renal NIRS Values 3 Hours After Caffeine
Time Frame: At 3 hours after caffeine dose
Renal NIRS values 3 hours after caffeine broken down by baseline average
At 3 hours after caffeine dose
Renal NIRS Values 4 Hours After Caffeine
Time Frame: At 4 hours after caffeine dose
Renal NIRS values 4 hours after caffeine broken down by baseline average
At 4 hours after caffeine dose
Renal NIRS Values 6 Hours After Caffeine
Time Frame: At 6 hours after caffeine dose
Renal NIRS values 6 hours after caffeine broken down by baseline average
At 6 hours after caffeine dose

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Investigators

  • Principal Investigator: Matthew W Harer, MD, University of Wisconsin, Madison

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

April 25, 2018

Primary Completion (Actual)

December 31, 2019

Study Completion (Actual)

December 31, 2019

Study Registration Dates

First Submitted

December 15, 2017

First Submitted That Met QC Criteria

December 22, 2017

First Posted (Actual)

December 27, 2017

Study Record Updates

Last Update Posted (Actual)

November 29, 2022

Last Update Submitted That Met QC Criteria

October 28, 2022

Last Verified

October 1, 2022

More Information

Terms related to this study

Other Study ID Numbers

  • 2017-0589
  • 2017-013 (Other Identifier: Meriter IRB)
  • A536757 (Other Identifier: UW- Madison)
  • SMPH/PEDIATRICS/PEDIATRICS (Other Identifier: UW Madison)

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

No

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

Yes

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Acute Kidney Injury

Clinical Trials on Near Infrared Spectroscopy

Subscribe